Sands Capital Announces $555 Million Close of Life Sciences Pulse Fund III

Fund partners with private companies helping transform how diseases are defined, diagnosed, and treated

ARLINGTON, Va.--()--Sands Capital, an active, long-term investor in leading innovative businesses globally, today announced the close of its third life sciences fund, Sands Capital Life Sciences Pulse Fund III (“Pulse III”), raising $555 million. Pulse III was met with high demand from both existing and new limited partners. This close increases total Pulse strategy capital commitments to $1.3 billion, including Sands Capital Life Sciences Pulse Fund (“Pulse I”) and Sands Capital Life Sciences Pulse Fund II (“Pulse II”). The team will continue investing with the same emphasis on private therapeutics, diagnostics, medical devices, and life sciences tools businesses, in support of the strategy’s mission to help transform how diseases are defined, diagnosed, and treated.

“The life sciences sector continues to innovate at a rapid pace, leading to breakthroughs that benefit both patients and society as a whole,” said Stephen Zachary, Managing Partner. “We are grateful to both the investors joining us in Pulse III and the talented management teams we’ve partnered with since the strategy’s inception.”

The Pulse investment team comprises senior professionals led by founders, operators, PhDs, and experienced investors with the ability to leverage the resources and capabilities of the entire firm to execute its strategy. The team also draws upon Sands Capital’s more than three decades of deep research and experience investing in innovation in public markets.

As of March 31, 2024, Sands Capital managed over $54 billion in public and private equity investments including more than $5 billion in life sciences and health care companies globally across all strategies.

About Sands Capital

Sands Capital is an active, long-term investor in leading innovative businesses globally. Our approach combines analytical rigor and creative thinking to identify high-quality growth businesses that are creating the future. Through an integrated investment platform spanning venture capital, private growth equity and public growth equity, we provide growth capital solutions to institutions and fund sponsors in more than 40 countries. Sands Capital is an independent, staff-owned firm founded in 1992 with offices in the Washington, D.C. area, San Francisco, London, and Singapore. www.sandscapital.com

Contacts

Chaneigh Bernard
pro-sandscapital@prosek.com

Release Summary

Sands Capital today announced the close of its third life sciences fund, Sands Capital Life Sciences Pulse Fund III.

Contacts

Chaneigh Bernard
pro-sandscapital@prosek.com